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Asenapine in the management of impulsivity and
aggressiveness in bipolar disorder and comorbid borderline
personality disorder: an open-label uncontrolled study
Andrea Agugliaa,b, Ludovico Mineoc, Alessandro Rodolicoc,
Maria S. Signorellic and Eugenio Agugliac
Borderline personality disorder (BPD) often co-occurres with
bipolar disorder (BD). Impulsivity and aggressiveness
represent core shared features and their pharmacological
management is mainly based on mood stabilizers and
antipsychotics, although scarce evidence is available for this
context of comorbidity. The aim of the present study was to
evaluate the role of Asenapine as an adjunctive drug for
reducing aggressiveness and impulsivity in a sample of Italian
BD type I outpatients with or without a comorbid BPD. This
was an observational 12-week open-label uncontrolled clinical
study carried out from April to October 2014 in two psychiatric
clinics in Sicily. Each patient was treated with asenapine at two
dose options, 5mg (twice daily) or 10mg (twice daily), and
concomitant ongoing medications were not discontinued. We
measured impulsivity using the Barratt Impulsiveness Scale
(BIS) and aggressiveness using the Aggressive Questionnaire
(AQ). For the analysis of our outcomes, patients were divided
into two groups: with or without comorbid BPD. Adjunctive
therapy was associated with a significant decrease of BIS and
AQ overall scores in the entire bipolar sample. Yet, there was
no significant difference in BIS and AQ reductions between
subgroups. Using a regression model, we observed that
concomitant BPD played a negative role on the Hostility
subscale and overall AQ score variations; otherwise, borderline
co-diagnosis was related positively to the reduction of physical
aggression. According to our post-hoc analysis, global
aggressiveness scores are less prone to decrease
in patients with a dual diagnosis, whereas physical
aggressiveness appears to be more responsive to the
add-on therapy in patients with comorbidity. Int Clin
Psychopharmacol 33:121–130 Copyright © 2018 The Author(s).
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Introduction
Bipolar disorder (BD) is a chronic mental illness with a
relapsing and remitting course often characterized by
comorbid psychopathological conditions. The US National
Comorbidity Survey Replication found that almost 93% of
respondents with BD fulfilled the criteria for at least
another Axis I Diagnostic and Statistical Manual of Mental
Disorders, 4th ed., text revision (DSM-IV-TR) diagnosis
(Merikangas et al., 2007), with higher rates for anxiety and
impulse control disorders. Analogously, cluster B person-
ality disorder features are evident in about one-third of
bipolar patients, with a greater prevalence of borderline
personality traits (Garno et al., 2005).
Borderline personality disorder (BPD) is a severe personality
dysfunction characterized by a pervasive pattern of instability
in affect regulation, impulse control, interpersonal relation-
ships, and self-image (Leichsenring et al., 2011).
A recent meta-analysis among 42 studies showed a wide
range of rates of comorbidity of these conditions (i.e. 0–62.5%
of BPD in BD and 0–62.5% of BD in BPD), eventually
quantifying the prevalence of BPD in patients with a
primary diagnosis of BD at 21.6% (95% confidence interval:
17.0–27.1) and the converse at 18.5% (95% confidence
interval: 12.7–26.1) (Fornaro et al., 2016).
These high rates of comorbidity, together with the relevant
heterogeneity of the data obtained by the available prevalence
studies, may be partially linked to errors in the clinical
assessment of both conditions and consequent misdiagnosis.
Differentiation of BD from BPD in fact represents a diag-
nostic challenge because of the overlapping of phenomen-
ological and clinical features such as emotional dysregulation,
mood instability, aggressiveness, impulsivity, unstable inter-
personal relationships, repeated self-injury, and suicidal
attempts. The relationship between these nosological entities
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is still a matter of academic debate, with some authors ques-
tioning the possibility of a real comorbidity, considering it as a
‘nosographic artifact’ and placing the borderline syndrome
under the bipolar spectrum (Akiskal, 2004; MacKinnon and
Pies, 2006; Perugi et al., 2013). In contrast, psychiatrists who
strongly advocate the categorization of BPD among person-
ality disorders underline specific psychopathological features
compared with BD spectrum subtypes, and warn clinicians
about the necessity of diagnostic evaluations able to detect
precise features in the phenomenology of shared symptoms
by integrating clinical practice with appropriate testing
methods (Paris, 2004; Fulford et al., 2015; Vöhringer et al.,
2016; Bayes and Parker, 2017; di Giacomo et al., 2017).
Moreover, differences in the course and longitudinal trajec-
tories of these conditions, patients’ family history, and
response to medication should be taken into account
(Hatchett, 2010; Renaud et al., 2012).
A considerable part of the overlapping symptoms pertains
to the dimension of impulsivity, although different pheno-
menological aspects of this domain have been described in
the two disorders.
Impulsivity in potentially self-damaging areas is listed in
DSM-V (American Psychiatric Association, 2013) as a diag-
nostic criterion for BPD and represents a clinical hallmark in
patients affected; it has been evaluated as extremely stable
over time and highly predictive of borderline psychopatho-
logy (Moeller et al., 2001; DeShong and Kurtz, 2013). In BD,
instead, impulsivity is believed to have a more episodic
course than in BPD (Swann, 2010), although higher levels of
impulsivity are recorded frequently during the interepisode
phase (Swann et al., 2004; Powers et al., 2013).
Furthermore, from a neuropsychological prospective,
differential patterns of impulsivity have been described
for depressive and manic episodes in BD with a pre-
valence of motor impulsivity (tendency to act on the spur
of the moment) related to mania and nonplanning
impulsivity (difficulty with planning actions carefully and
thinking about the consequences of actions) related to
depression. This latter component of impulsivity also
seems to be prevailing in BPD (Swann et al., 2004; Flory
et al., 2006; Wilson et al., 2007).
Impulsivity-related symptoms appear to be closely linked to
mood lability and they often manifest as inappropriate sexual
behaviors in both BD and BPD, although impulsivity may
also consist of physical, financial, binge eating-related, or
aggressive acts (Ghaemi et al., 2014; Fornaro et al., 2016). In
fact, impulsivity is considered the main psychopathological
mediator of aggressiveness in both conditions (Goodman and
New, 2000; Wilson et al., 2007; Látalová, 2009; Barker et al.,
2015).
Aggressiveness against self or against others is one of the core
components of BPD accounting for a significant proportion
of morbidity and mortality associated with this disorder
(Goodman et al., 2010). In BPD, aggressiveness is mainly of
the impulsive type, driven by lack of behavioral inhibition
and generally triggered by environmental overstimulation
and stress (Wilson et al., 2007; Latalova and Prasko, 2010).
Similarly, in BD, most of the aggressiveness is apparently
impulsive, occurring largely during acute episodes,
independent of psychosis. However, aggressive beha-
viors may also be present in euthymic phases, suggesting
that impulsive aggressiveness is not only state related but
also a trait component of BD (Grunebaum et al., 2006;
Najt et al., 2007; Látalová, 2009).
Comorbidity between BD and BPD has already been
described as an adjunctive detrimental factor for the
clinical course and evolution of both disorders; patients
with BD and comorbid BPD present an earlier onset of
disease, higher self-harming behavior and suicidality,
greater hostility, lower rates of stabilization and treatment
adherence, and a more remarkable risk of substance use
in comparison with BD alone (Vieta et al., 2001; Swartz
et al., 2005; Goldberg and Garno, 2009; Latalova et al.,
2013; McDermid et al., 2015).
To date, only a few studies have investigated
the potential contribution of cluster B disorders to
impulsivity/aggressiveness in mood disorders (including BDs)
converging on higher levels of impulsivity/aggressiveness
in comorbid patients compared with those with only a mood
disorder diagnosis (Henry et al., 2001; Wilson et al., 2007;
Garno et al., 2008).
Undoubtedly, in this subgroup of patients, control of
impulsive–aggressive behaviors is a therapeutic priority,
particularly to prevent risks of self-injuries or harm to others.
On the basis of the available data for each single disorder
(Prado-Lima, 2009; Kendall et al., 2010; Lieb et al., 2010;
Leichsenring et al., 2011), some mood stabilizers (espe-
cially lithium carbonate, divalproex sodium and valproate,
carbamazepine, lamotrigine) and second-generation anti-
psychotics (SGAs) (risperidone, olanzapine, quetiapine)
may be considered suitable pharmacotherapeutic options
targeting these shared symptom dimensions, even with
different degrees of evidence.
Antagonism to 5-HT2A receptors in mitigating aggressive–
impulsive behaviors (Blake and Grafman, 2004; Siever,
2008) makes SGAs a valid alternative in this subgroup
of patients as the use of other available drugs (selective
serotonin reuptake inhibitors, serotonin norepinephrine
reuptake inhibitors), interfering with the serotoninergic
system in the modulation of aggressiveness-impulsivity
neural circuitry, is not generally recommended.
The proven efficacy and tolerability of asenapine in the
treatment of acute mania in BD (Samalin et al., 2013;
Scheidemantel et al., 2015), along with some promising
evidences of its efficacy in BPD (Martín-Blanco et al.,
2014; Bozzatello et al., 2017), led us to speculate about the
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potential utility of this new antipsychotic as a drug option
for patients with BPD alone or in comorbidity with BD.
Recently approved by the US Food and Drug Administration
for the treatment of schizophrenia and BD, asenapine
presents a peculiar receptor binding profile with a
5-HT2A :D2 affinity ratio similar to other SGA, but a higher
affinity for serotonergic, α1,2 adrenergic receptors (Weber and
McCormack, 2009; Timpe and Chopra, 2010). Together with
clozapine, asenapine is the unique antipsychotic presenting a
D4/D2 affinity ratio of more than 1 that has been purported to
confer an antiaggression effect (El-Mallakh and McKenzie,
2013). This latter hypothesis was proposed in the light of the
proven superiority of clozapine – in both open and rando-
mized trials (Frogley et al., 2012) – over other antipsychotic
comparators.
Finally, asenapine has shown a more favorable tolerability
profile with a lower propensity to cause weight gain, prolactin
elevation, or QTc prolongation compared with most SGA
(Gonzalez et al., 2011; Citrome, 2014).
The aim of this study was to evaluate the efficacy of ase-
napine as an adjunctive drug for reducing aggressiveness
and impulsivity in a group of Italian outpatients with BD
type I with or without a comorbid BPD.
Patients and methods
Population
This was an observational, 12-week open-label uncontrolled
clinical study, carried out from April to October 2014. Patients,
aged between 18 and 75 years with a previous diagnosis of BD
type I, were recruited into the adult psychiatric outpatient
services of Catania University Hospital and Siracusa City
Hospital. All patients included in the study underwent
assessment with the Structured Clinical Interview for DSM-
IV (SCID-I) (First et al., 2002) and the Italian version of the
Mood Disorder Questionnaire (Hirschfeld, 2002) to confirm
their past diagnosis of BD type I by means of two different
screening instruments.
To evaluate the comorbidity with BPD, we used the
Structured Clinical Interview for DSM-IV Axis II Disorders
(SCID-II) (First et al., 1997) and the Borderline Syndrome
Index (BSI), a 52-item, yes–no, self-report questionnaire
used widely by clinicians as a rapidly administered and
scored instrument for assessing borderline psychopathology.
Consistent with the available literature data, we set a BSI
cutoff score at 25 to differentiate the two groups (Conte
et al., 1980; Edell, 1984).
Exclusion criteria were as follows: current episode of BD
(depressive, manic, mixed), occurrence of severe physical
conditions (i.e. neurological disease, mental deficiency,
and other neurological conditions), a past or current
schizophrenia spectrum disorder or other psychotic dis-
order; a past or current mental disorder because of a
medical condition; current mental retardation or other
significant neurocognitive disturbances; current severe
physical illness; and concurrent alcohol and/or other
substance abuse/dependence history of mental disorders
because of a medical condition. Pregnant and sexually
active women unwilling to use an effective means of
contraception were also excluded.
Design and measures
The sample selected for this study included 50 patients
with a primary diagnosis of BD type I in the euthymic
phase. Recruitment of patients was performed on a
consecutive basis. After the assessment for the borderline
traits, they were divided into two groups: patients with a
diagnosis of BD type I and patients with BD type I and
BPD (BSI> 25).
Each patient was treated with asenapine at two dose
options, 5 mg (twice daily) or 10mg (twice daily), accord-
ing to the clinical judgment of the investigator evaluating
the clinical course for a 12-week period. Concomitant
medications started before inclusion in the study could be
continued by the patients. Psychiatric interviews, clinical
examination, scale administration, and assessment of
medical history were performed by a trained psychiatric
resident with at least 5 years of postgraduate clinical
experience in the outpatient clinical setting.
Body weight, height, and waist circumference were also
measured. Weight of the undressed patients was mea-
sured in fasting condition; height was measured barefoot.
To evaluate central adiposity, waist circumference was
measured between the inferior margin of the ribs and the
superior border of the iliac crest, at minimal respiration.
BMI, defined as the ratio of body weight (in kg) and
height (in m2), was calculated.
Aggressiveness was evaluated using the Italian version
(Fossati et al., 2003) of the Aggression Questionnaire (AQ)
(Buss and Perry, 1992). This is a four-factor model ques-
tionnaire consisting of 29 items scored on a five-point Likert
scale, from extremely uncharacteristic of me=1 to extremely
characteristic of me=5 (with some items scored in reverse),
that provides a global measure of aggressiveness and four
subscales: Physical Aggressiveness (PA, nine items), Verbal
Aggressiveness (VA, five items), Anger (A, seven items), and
Hostility (H, eight items).
Impulsivity was evaluated using he Italian version of the
BIS-11 (Patton et al., 1995; Fossati et al., 2001). This self-
report questionnaire consists of 30 items, scored on a
four-point Likert scale (rarely/never – 1, occasionally – 2,
often – 3, almost always/always – 4). To minimize the risk
of response bias, 10 of the items are scored reversely
(rarely/never – 4, occasionally – 3, often – 2, almost
always/always – 1). The scale measures the three sub-
dimensions of impulsivity: attentional (eight items; inat-
tention and cognitive instability), motor (11 items; motor
impulsivity, and lack of perseverance), and nonplanning
(11 items; lack of self-control and intolerance of cognitive
complexity).
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Aggressiveness and impulsivity levels were assessed at
baseline (V0) and at 12 weeks (V1). A telephone number was
provided to each patient to report any possible side effects or
to provide any useful information about the course of the
illness at any time: if a patient had shown any significant
clinical symptom, he or she would have been immediately
visited. In any case, at 6 weeks, a psychiatric visit was
planned to evaluate the course of illness and tolerability.
The study was carried out according to the principles of the
Declaration of Helsinki. Participants did not receive any
compensation for the study. Patients expressed their will-
ingness to participate in the study by signing a written
consent, after being thoroughly informed about the aim and
procedures of the study. The study design was reviewed by
the local ethic committee.
Safety
Adverse events were recorded on the basis of spontaneous
report or investigator observations. We considered an
adverse event as treatment-emergent adverse event if it
was newly reported after open-label baseline or reported
to have worsened in severity since open-label baseline.
Predefined treatment-emergent adverse events of inter-
est in the study were dizziness, insomnia, somnolence/
hypersomnia/sedation combined, oral hypoesthesia/dys-
geusia, extra-pyramidal symptoms (EPS), and incidence
of clinically significant weight increase defined by an
increase superior 7% from baseline. EPS were assessed
using a clinician-administered Abnormal Involuntary
Movement Scale (Munetz and Benjamin, 1988), the
Barnes Akathisia Scale (Barnes, 2003), and the Simpson-
Angus Scale (Simpson et al., 1970).
Statistical analysis
Descriptive data were summarized as number of patients and
percentage (%) or mean±SD. Comparisons within groups
were performed using a paired-samples t-test. Comparisons
between groups (with or without BD) were performed
using an independent-samples t-test (continuous variables:
score AQ-PA, AQ-VA, AQ-A, AQ-H, AQ-total, BIS) or the
χ2-test (dichotomous variables: percentage of patients who
improved). To determine factors significantly related to the
changes of the different scores, general linear models were
applied: correlation testing was performed using analysis of
covariance models with sex, education level, borderline per-
sonality diagnosis, and Mood Disorder Questionnaire score as
fixed factors and age, SCID-II score, BSI score, and baseline
scores for each subscale (AQ-PA, AQ-VA, AQ-A, AQ-H) as
covariates. A significance level of 0.05 was used for each test.
For all the analyses, IBM SPSS Statistics forWindows, version
20.0 (IBM Corp., Armonk, New York, USA), was used.
Results
Fifty BD type I patients were included in the study; 35
(70%) had BPD comorbidity (BD-I/BPD patients) and 15
(30%) patients had only BD type I diagnosis (BD patients).
Clinical and sociodemographic characteristics of the
recruited patients are reported in Table 1.
At the beginning of the study, only three (6%) patients
were drug-free, 30 (60%) patients were receiving mood
stabilizers (lithium or valproic acid at therapeutic range),
14 (28%) patients were receiving mood stabilizers plus
benzodiazepines, one patient was receiving mood stabi-
lizers (lithium 600mg and carbamazepine 400 mg) and
serotonin norepinephrine reuptake inhibitors (venlafax-
ine at 75 mg), and two patients were receiving mood
stabilizers with selective serotonin reuptake inhibitors
(lithium 750mg plus escitalopram 10mg and valproic
acid 1000 mg plus sertraline 75 mg) and benzodiazepines.
Lack of efficacy of previous medications in modulating
impulsive–aggressive behaviors was reported as the main
reason for starting therapy. The mean daily dose of ase-
napine at T0 was 14.8 mg/day (SD= 2.5) for the group
BD type I/BPD and 15.3 mg/day (SD= 2.3) for the group
BD. All patients completed the study and no medication
regimen changes were made during the trial.
A significant reduction in the AQ and BIS overall score
was found in the total sample (P< 0.001) and for each
subgroup (BD type I P< 0.001 and BD type I/BPD
P< 0.001). This finding was also obtained for all AQ
subscales (PA, VA, A, and H subscales) at paired t-test
analysis at T1 score versus baseline.
No significant differences in the AQ-total and subscales
(AQ-total PA, VA, A, H) score variations from baseline to
T1 were found between groups as shown in Table 2.
Some subscales scores differed significantly between
groups at baseline as shown in Table 3.
It should be noted that the difference in the baseline levels
of impulsivity between the two groups (BD type I vs. BD
type I/BPD) was not significant (P=0.563), whereas AQ-
total score and two subscales scores (AQ-H, AQ-A) were
different between groups (BD type I vs. BD type I\BPD).
Considering the statistically significant difference of various
baseline scores, it was not possible to compare row values of
AQ and BIS scales and subscales. Thus, it was more rea-
sonable to compare the scores difference before and after
the treatment. To assess the role of candidate predictors in
scores’ reduction, we investigated whether any baseline
variable could play a role in modulating a decrease in scores
with an analysis of covariance model, which is presented
in Table 4. The borderline concomitant diagnosis seems
to play a negative role in the H subscale variation,
F(1,39)=12.067, P= 0.001, and on overall AQ score varia-
tion, F(1,39)=13.683, P=0.001. Indeed, the reduction of
these is more relevant in BD patients without BPD
comorbidity. Otherwise, even if not strictly significant
(P=0.053), borderline co-diagnosis might be related posi-
tively to PA reduction in patients treated with asenapine,
considering a more relevant decrease in its subscale scores
in comorbid patients (80.0 vs. 97.1%, P=0.041).
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Side effects
No serious adverse effect was recorded and there was no
discontinuation of treatment. Nineteen (38%) patients
reported increased somnolence/sedation, 14 (28%) reported
oral hypoesthesia, 10 (20%) reported dysgeusia, and eight
(16%) patients reported sporadic dizziness. No movement
disorder was spontaneously reported or detected after
clinical evaluation with dedicated scales. At T1, we did not
find any significant weight variation, t(49)=0.884, P=0.381,
two tails. The mean BMI at baseline was 28.6 (2.4),
whereas at 12 weeks; it was slightly reduced, 28.3 (3.2).
Discussion
To the best of our knowledge, this open-label trial is the
first prospective study on pharmacological management of
impulsivity and aggressiveness in patients affected by BD
type I and comorbid BPD. Furthermore, although there
are already two studies that have investigated the efficacy
and tolerability of asenapine in BPD (Martín-Blanco et al.,
2014; Bozzatello et al., 2017), the present work is the only
one available on the use of asenapine as an adjunctive
drug in pharmacotherapy of BP patients with BPD.
In our sample, we observed a 70% rate of BPD diagnosis
among patients with BD type I. This is quite a high rate
compared with the mean percentage of this comorbidity
reported by the most recent meta-analysis on this topic
(Fornaro et al., 2016). However, in some hospital-based
studies included in that work, BD/BPD comorbidity pre-
valence reaches percentages as high as ours (Zimmerman
and Mattia, 1999; Benazzi, 2000; Wilson et al., 2007).
Finally, differences in assessment instruments used, a
small sample size, and missing long-term follow-up for the
diagnostic validation of both conditions may account for
this discrepancy. Moreover, we hypothesize that a further
reason behind this difference might be the method of
patient recruitment. Patients were recruited on a con-
secutive basis and this might have led to selection bias. To
partially overcome this issue, statistical evaluations were
performed by correcting scores of scales for BPD diagnosis.
The co-occurrence of BD and BPD appears to be bidir-
ectional in nature, irrespective of the index population
studied (BPD with BD or vice-versa) (Garno et al., 2005;
Paris et al., 2007) and, along with the high rate of over-
lapping symptoms, continues to foster the debate on the
underlying nature of the relationship between these
conditions. However, most recent trends in the psycho-
pathological literature tend to consider BD and BPD as
two separate nosographic entities with distinguishable
clinical and diagnostic features (Paris et al., 2007; Bassett,
2012; Ghaemi et al., 2014). In particular, quality and
Table 1 Demographic and clinical data for the study sample
BD only (N=15) BD and BPD (N=35) Total (N=50) P value
Sex [n (%)]
Female 8 (53.3) 15 (42.9) 23 (46.0) 0.496
Male 7 (46.7) 20 (57.1) 27 (54.0)
Age (years)
Mean (SD) 43.1 (14.04) 47.6 (13.08) 46.2 (13.40) 0.277
Median 45 50 48
Minimum–maximum 20–68 21–72 20–72
Education [n (%)]
Elementary school – 2 (5.7) 2 (4.0) 0.462
Middle school – 3 (8.6) 3 (6.0)
High school 8 (53.3) 18 (51.40) 26 (52.0)
Graduatiom 7 (46.7) 12 (34.3) 19 (38.0)
Most recent episode [n (%)]
Depressive – 4 (11.4) 4 (8.0) 0.069
Depressive with mixed features 1 (6.7) 9 (25.7) 10 (20.0)
Mania 5 (33.3) 12 (37.1) 18 (36.0)
Mania with mixed features 9 (60.0) 9 (25.7) 18 (36.0)
Concomitant therapy with asenapine
No concomitant therapy 1 (6.7) 2 (5.7) 3 (6.0) 0.831
Mood stabilizer 10 (66.7) 20 (57.1) 30 (60.0)
Mood stabilizer +BDZ 4 (26.7) 10 (28.6) 14 (28)
Mood stabilizer +SNRI – 1 (2.9) 1 (2.0)
Mood stabilizer +SSRI +BDZ – 2 (5.7) 2 (4.0)
Previous substance abuse [n (%)] 6 11 17 0.746
BD, bipolar disorder; BDZ, benzodiazepines; BPD, borderline peronality disorder; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake
inhibitors.
Table 2 Impulsivity and aggression score variations: differences
between BD and BD/BPD
BD only (N=15) BD and BPD (N=35)
P value
(two-sided t-test)
ΔAQ-PA −7.1 (7.72) −7.0 (4.02) 0.962
ΔAQ-VA −5.9 (5.08) −4.3 (3.99) 0.287
ΔAQ-A −4.8 (4.16) −6.8 (3.94) 0.121
ΔAQ-H −7.2 (6.98) −7.2 (5.55) 1
ΔAQ −24.9 (16.57) −25.3 (11.37) 0.933
ΔBIS −15.7 (11.06) −13.6 (11.47) 0.544
AQ, Aggression Questionnaire; AQ-A, Aggression Questionnaire-Anger;
AQ-H, Aggression Questionnaire-Hostility; AQ-PA, Aggression Questionnaire-
Physical Aggression; AQ-VA, Aggression Questionnaire-Verbal Aggression;
BD, bipolar disorder; BIS, Barratt Impulsiveness Scale; BPD, borderline peronality
disorder.
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temporal pattern of mood swing episodes, types and
trigger factors of impulsive behaviors, psychotic dimen-
sion, and longitudinal course (onset and prognosis) of
disease have been targeted as the main parameters useful
to distinguish the two diagnoses (Hatchett, 2010; Biskin
and Paris, 2012; di Giacomo et al., 2017). It is also true
that although distinguishing BD type I from BPD is
generally less problematic, reflecting the severity
and frequent psychotic nature of manic symptoms, the
differential diagnosis of BD type 2 from BPD can be
particularly difficult, especially in the event of few
hypomanic symptoms, prevalence of mixed features, and
ultra-rapid or ultradian cycling (Zimmerman and Morgan,
2013).
Table 3 Baseline scores of impulsivity and aggressiveness in BD and BD/BPD
BD only (N=15) BD and BPD (N=35) Total (N=50) P value (two-sided t-test)
SCID-II
Mean (SD) 9.8 (1.82) 10.6 (1.67) 10.4 (1.74) 0.137
Median 10 11 11
Minimum–maximum 5–13 7–13 5–13
BSI
Mean (SD) 16.2 (8.09) 37.9 (7.08) 31.4 (12.42) <0.001*
Median 20 40 33
Minimum–maximum 4–25 26–50 4–50
MDQ [n (%)]
Negative 6 (40.0) 2 (5.7) 8 (16.0) 0.002*
Positive 9 (60.0) 33 (94.3) 42 (84.0)
AQ-PA
Mean (SD) 23.7 (8.41) 29.5 (6.49) 27.8 (7.52) 0.012*
Median 23 32 30.5
Minimum–maximum 13–36 14–43 13–43
AQ-VA
Mean (SD) 17.3 (7.48) 19.3 (3.83) 18.7 (5.20) 0.22
Median 19 20 20
Minimum–maximum 5–28 10–28 5–28
AQ-A
Mean (SD) 21.5 (5.77) 25.6 (4.05) 24.4 (4.94) 0.007*
Median 21 27 25.5
Minimum–maximum 13–32 14–34 13–34
AQ-H
Mean (SD) 21.2 (6.92) 27.0 (5.16) 25.3 (6.28) 0.002*
Median 20 28 25.5
Minimum–maximum 8–31 18–35 8–35
AQ-total
Mean (SD) 83.8 (22.23) 101.4 (14.09) 96.1 (18.58) 0.001*
Median 89 104 101
Minimum–maximum 43–114 66–129 43–129
BIS
Mean (SD) 67.2 (10.27) 69.2 (11.45) 68.6 (11.04) 0.563
Median 64 71 69
Minimum–maximum 56–92 44–84 44–92
AQ-A, Aggression Questionnair-Anger; AQ-H, Aggression Questionnaire-Hostility; AQ-PA, Aggression Questionnaire-Physical Aggression; AQ-VA, Aggression
Questionnaire-Verbal Aggression; BD, bipolar disorder; BIS, Barratt Impulsiveness scale; BPD, borderline peronality disorder; BSI, Brief Symptom Inventory; MDQ, Mood
Disorder Questionnaire; SCID-II, Structured Clinical Interview for DSM-IV Axis II Disorders.
*P value indicates significant.
Table 4 ANCOVA model of AQ total score variation
Sum of squares d.f. Mean of squares F Significance η2
Corrected model 5627.573 55 562.757 8.393 0.000 0.683
Intercept 1410.541 1 1410.541 21.037 0.000 0.350
Age 132.139 1 132.139 1.971 0.168 0.048
Sex 152.895 1 152.895 2.280 0.139 0.055
Education 153.379 3 917.459 0.762 0.522 0.055
Borderline personality disorder 917.459 1 917.459 13.683 0.001 0.260
MDQ 44.945 1 44.945 0.670 0.418 0.017
SCID-II 54.827 1 54.827 0.818 0.371 0.021
BSI 102.646 1 102.646 1.531 0.223 0.038
AQ-total score 2807.590 1 2807.590 41.872 0.000 0.518
Error 2615.007 39 67.051 – – –
Total 40 045.000 50 – – – –
Corrected total 8242.580 49 – – – –
R2=0.683 (corrected R2=0.601)
AQ, Aggression Questionnaire; BSI, Brief Symptom Inventory; MDQ, Mood Disorder Questionnaire; SCID-II, Structured Clinical Interview for DSM-II.
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In the present study, patients with BD type I/BPD
showed significantly higher mean scores for the total
scale of AQ and on PA and H subscales in comparison
with pure BD patients; levels of impulsivity between the
two groups were instead found to be similar. These
findings are partially in line with previous studies (Henry
et al., 2001; Wilson et al., 2007). In particular, a recent
study by Carpiniello et al. (2011) reported that patients
with a primary diagnosis of BD (type 1 or type 2) and
additional BPD obtained significantly higher scores on
both the AQ and the BIS-11 scales compared with those
with bipolar alone or with any other concomitant per-
sonality disorder. Furthermore, bipolar patients with a
borderline component reported a higher rate of suicide
attempts in their history compared with the other two
groups. Thus, a particular prominence of impulsivity and
aggressiveness in the clinical picture of a patient with BD
should lead to the suspicion, often overlooked in the
common medical practice (Zimmerman and Mattia,
1999), of a comorbid borderline personality disorder.
Undoubtedly, detection of this specific subgroup of
patients appears to be of considerable importance even to
address the increased risk for self-injuries and harmful
behaviors, already related to the single disorder.
In treating patients with both BD and BPD, clinicians
have to rely on scarce literature evidence on the prefer-
able pharmacotherapy option.
To our knowledge, very few studies have been carried
out so far to evaluate the efficacy of some drugs in
treating this comorbidity. In a 6-month controlled study
of Frankenburg and Zanarini (2002), which included 30
BPD patients with comorbid BD type II, prominent
effects of valproate (plasma levels were in 50–100 g/ml)
were detected on interpersonal sensitivity, anger, hosti-
lity, and aggressiveness. Preston et al. (2004), instead
showed that lamotrigine was effective in reducing bor-
derline dimensions in bipolar patients who qualified for a
concomitant diagnosis of BPD after a retrospective eva-
luation. In terms of antipsychotic use in this particular
clinical context, there is only a very recent case-report
of a patient with a BD/BPD comorbidity, complicated
by substance abuse, who experienced a significant
improvement after off-label prescription of aripiprazole
long acting injection therapy, although changes in spe-
cific symptom dimensions were not evaluated (Martinez
and Caballero, 2017).
Different from the above-mentioned studies, our open-
label trial evaluated exclusively the efficacy of asenapine
as an adjunctive drug in improving the control of
impulsive–aggressive behaviors in BD type I patients –
with or without a comorbid BPD – who were already
taking psychotropic medications (in particular mood
stabilizers) as a therapeutic strategy.
After 12 weeks of administration, asenapine was proven
to be effective in reducing impulsivity and aggressive-
ness levels in both subgroups of patients.
We recorded a significant decrease for each subdimen-
sion of aggressiveness (PA, VA, A, H) and for impulsivity,
irrespective of concomitant BPD. However, after con-
trolling for confounding baseline factors, the magnitude
of variations was influenced by BPD co-diagnosis.
Borderline component was associated negatively with
total aggressiveness and H score decrease, but correlated
positively to PA score reduction.
Indeed, among patients presenting a significant response
(considered as a 50% score reduction in the proper sub-
scale) in reduction of the physical aggressiveness com-
ponent, we found a higher percentage of patients with
comorbid personality disorder. Instead, percentages of
responders in all remaining subscale did not differ sig-
nificantly between the two groups.
This finding may be related to the ability of asenapine to
target typical features of borderline personality involved in
triggering physical aggressive behaviors. We may assume that
asenapine – probably because of its antipsychotic properties –
may exert a modulating effect on specific BPD features
involved in physical impulsive–aggressive acts, such as reality
distortion, affect instability, and feelings of emptiness as
shown in a recent study byMartín-Blanco et al. (2014). Among
these borderline traits, the feeling of emptiness appears to be
involved in eliciting self-mutilations and para-suicidal ideation,
and it has been reported as mostly unresponsive to treatment
(Stoffers et al., 2010).
However, the opposite finding of a lesser magnitude of
variation in total aggressiveness score in BD type I/BPD
sample may be interpreted considering the BPD component
as an additional obstacle to drug efficacy in modulating these
dimensions. Furthermore, it probably implies a different
selectivity of asenapine in targeting physical aggressiveness-
related neural mechanisms (Blake and Grafman, 2004;
Siever, 2008), compared with nonphysical ones, although
further investigations are needed to clarify this aspect.
A resistance of BPD patients in achieving a satisfying
improvement in aggressiveness control was also reported in
a study carried out to evaluate the efficacy and tolerability of
asenapine in comparison with olanzapine, the most broadly
studied antipsychotic in BPD. Although asenapine and
olanzapine were shown to have a similar efficacy, with
a superiority of asenapine in treating affective instability,
neither drug significantly improved aggressive symptoms,
but an analysis accounting for each single subcomponent of
the aggressiveness dimension was not carried out.
A beneficial use of asenapine in reducing physical aggres-
siveness was also recently shown in a prospective naturalist
pilot study carried out on a sample of hospitalized psychiatric
patients with different diagnoses and a current history of
aggressive behavior (Amon et al., 2017). Among the patients
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included in the study, those receiving asenapine, irrespective
of diagnosis, experienced a greater reduction in the level of
aggressive or disruptive behavior than patients receiving
treatment as usual, but this reached statistical significance
only for PA. However, no patient with comorbid or pure
BPD was included in that study.
In our study, asenapine showed a good tolerability and safety
profile, with no patient experiencing EPS or weight gain.
These findings represent further confirmations of the
quite benign safety profile of asenapine, with limited
effects on body weight and metabolism (Shahid et al.,
2009; Tarazi and Stahl, 2012). This does not constitute a
simple secondary advantage considering the impact of
fattening and body image changes on discontinuation of
therapy by BD and BPD patients (Zittel and Westen,
2005; Torrent et al., 2008; Shrivastava and Johnston,
2010).
Limitations
There are many limitations that must be taken into
consideration when interpreting our results.
First of all, this is an open-label study and it cannot be
compared with a randomized-controlled trial where rando-
mization and allocation concealment protect from various
biases. Indeed, our baseline scores differ significantly
between groups. Lack of sufficient numbers of patients
made it impossible to match patients with and without
borderline traits. Moreover, our small sample might be not
sufficient to highlight differences in scale score variations
between the two groups, even if they may be present.
Second, a systematic administration of clinical evaluation
is missing. Finally, the role of concomitant medication
was not analyzed and might affect asenapine response.
The strength of this study is the sample homogeneity, by
recruiting only patients clinically judged to be in the
euthymic phase and considered to be in stable remission,
whereas different polarity of the current episode is a
factor that can influence the expression of aggressiveness
and impulsivity. The same remark can be made on the
exclusion of patients affected by comorbid alcohol and/or
drug abuse/dependence, considering the high prevalence
of those in patients similar to ours.
Conclusion
An accurate clinical definition of comorbidity between BD
and BPD is extremely important as the two conditions
require different therapeutic modalities, respectively, a
mood stabilizer and a cognitive-behavioral psychotherapy
being prioritized. Misdiagnosis can deprive the patient
of potentially effective treatment or conversely lead to
unnecessary and improper pharmacological prescription. A
qualitative and quantitative evaluation of impulsive and
aggressive behaviors in BD patients may help clinicians
when there is a reasonable suspicion of a comorbid BPD,
especially during the euthymic phases of disease. At the
same time, the presence of comorbidity might be an
opportunity to differentiate psychopathological assets that
belong to each condition. Furthermore, given the burden
of impulsivity and aggressiveness in the morbidity and
mortality associated with these disorders, in the pharma-
cotherapy approach, clinicians should consider drugs able
to specifically target these dimensions without jeopardiz-
ing other treatment outcomes. Our results suggest a
promising role of asenapine in managing.
Aggressive–impulsive behaviors in bipolar patients, with
or without comorbid BPD, posing itself as suitable alter-
native to other SGA commonly used in these conditions,
especially because of its safety and tolerability profile.
Further studies are still needed to increase the level of
evidence and to assess the efficacy of asenapine during the
active phases of BD. Finally, as described in the limitations
of the study, it is necessary to conduct methodologically
superior trials to moderate the effect of cofounding variables.
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